No abstract available
Keywords:
B cell depleting therapies; B cell targeted therapy; Bruton tyrosine kinase (BTK); CAR (chimeric antigen receptor) T cells; NMO (neuromyelitis optica); SLE - systemic lupus erythematosus; multiple sclerosis; rituximab.
MeSH terms
-
Autoimmune Diseases* / drug therapy
-
Humans
-
Neuromyelitis Optica*
-
Spinal Cord
Grants and funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.